ロード中...
Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
The purpose of this study is to characterize adverse events (AEs) of clinical interest reported with ceftolozane-tazobactam and ceftazidime-avibactam, as an aid in monitoring patients affected by severe multidrug-resistant Gram-negative infections. We queried the worldwide FDA Adverse Event Reportin...
保存先:
| 出版年: | Eur J Clin Microbiol Infect Dis |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Berlin Heidelberg
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8139903/ https://ncbi.nlm.nih.gov/pubmed/33415492 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10096-020-04149-3 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|